This meta-analysis demonstrated that addition of EGFR inhibitors to chemotherapy increased the risk of severe toxicity and risk of treatment-related death (although this was numerically small), with an increased incidence of grade 3/4 skin rash and diarrhoea observed. The gene discussed is EGFR; the disease is Skin rash.